Phase I Clinical Study Combining L19-IL2 With Stereotactic Ablative Body Radiotherapy in Patients With Oligometastatic Solid Tumor

Trial Profile

Phase I Clinical Study Combining L19-IL2 With Stereotactic Ablative Body Radiotherapy in Patients With Oligometastatic Solid Tumor

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs L19-IL2 fusion protein (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms L19-IL2
  • Most Recent Events

    • 30 May 2017 Status changed from discontinued to completed.
    • 22 May 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
    • 22 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top